Peters, S

Pujol, J-L

Dafni, U

Dómine, M

Popat, S

Reck, M

Andrade, J

Becker, A

Moro-Sibilot, D

Curioni-Fontecedro, A

Molinier, O

Nackaerts, K

Mollá, A Insa

Gervais, R

Vivanco, G López

Madelaine, J

Mazieres, J

Faehling, M

Griesinger, F

Majem, M

Larriba, J L González

Pulla, M Provencio

Vervita, K

Roschitzki-Voser, H

Ruepp, B

Mitchell, Paul L R

Stahel, R A

Le Pechoux, C

De Ruysscher, D

2022

Concurrent chemotherapy and thoracic radiotherapy followed by prophylactic cranial irradiation (PCI) is the standard treatment in limited-disease small-cell lung cancer (LD-SCLC), with 5-year overall survival (OS) of only 25-33%. STIMULI is a 1:1 randomised phase II trial aiming to demonstrate superiority of consolidation combination immunotherapy versus observation after chemo-radiotherapy plus PCI (protocol amendment-1). Consolidation immunotherapy consisted of four cycles of nivolumab (1 mg/kg, every three weeks (Q3W)) plus ipilimumab (3 mg/kg, Q3W), followed by nivolumab monotherapy (240 mg, Q2W) for up to 12months. Patient recruitment closed prematurely due to slow accrual and the statistical analyses plan was updated to address progression-free survival (PFS) as the only primary endpoint. Of the 222 patients enrolled, 153 were randomised (78:experimental;75:observation). Among the randomised patients, median age was 62 years, 60% males, 34%/65% current/former smokers, 31%/66% PS 0/1. Up to 25/May/2020 (median follow-up 22.4months), 40 PFS events were observed in the experimental arm, with median PFS 10.7months (95%CI 7.0-Not Estimable(NE)) versus 42 events and median 14.5months (8.2-NE) in the observation, HR=1.02 (0.66-1.58), 2-sided p=0.93. With updated follow-up (03/June/2021; median: 35months), median OS was not reached in the experimental arm, while it was 32.1 months (26.1-NE) in observation, with HR=0.95 (0.59-1.52), p=0.82. In the experimental arm, median time-to-treatment-discontinuation was only 1.7 months. Grade≥3 adverse events were experienced by 62% pts in experimental and 25% in observation arm, with 4 and 1 fatal, respectively. The STIMULI trial did not meet its primary endpoint of improving PFS with nivolumab-ipilimumab consolidation after chemo-radiotherapy in LD-SCLC. A short period on active treatment related to toxicity and treatment discontinuation likely affected the efficacy results.

Annals of Oncology : Official Journal of the European Society for Medical Oncology 2022; 33(1): 67-79

Annals of Oncology

https://ahro.austin.org.au/austinjspui/handle/1/27569

Ipilimumab

Limited disease

Nivolumab

Randomised clinical trial

SCLC

Small cell lung cancer

Consolidation nivolumab and ipilimumab versus observation in limited-disease small cell lung cancer after chemo-radiotherapy - Results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial.

Journal Article